e-learning
resources
Vienna 2009
Monday, 14.09.2009
Pathobiology of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
VIP greatly attenuates monocrotaline-induced pulmonary vasculopathy in rats
S. Hamidi, A. Szema, M. Mirza, S. Said (Stony Brook, Northport, United States Of America)
Source:
Annual Congress 2009 - Pathobiology of pulmonary hypertension
Session:
Pathobiology of pulmonary hypertension
Session type:
Oral Presentation
Number:
1585
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Hamidi, A. Szema, M. Mirza, S. Said (Stony Brook, Northport, United States Of America). VIP greatly attenuates monocrotaline-induced pulmonary vasculopathy in rats. Eur Respir J 2009; 34: Suppl. 53, 1585
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Genistein rescues pulmonary hypertension and attenuates abnormal vasoconstriction in rats lungs
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats
Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair
Year: 2007
Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms
Year: 2012
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
Source: Eur Respir J 2011; 37: 1104-1118
Year: 2011
Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats
Source: Eur Respir J 2009; 34: 731
Year: 2009
Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018
VIP prevents and reverses monocrotaline-induced PAH: Further protection by combination with bosentan
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Effects of BMPR-II signal transduction in the pulmonary vascular remodeling of monocrotaline induced pulmonary hypertension in rats
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil
Source: Eur Respir J 2010; 36: 800-807
Year: 2010
Ghrelin protects against bleomycin-induced pulmonary fibrosis in mice
Source: International Congress 2017 – Lung fibrosis: basic science
Year: 2017
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
Reversibility of the monocrotaline pulmonary hypertension rat model
Source: Eur Respir J 2013; 42: 553-556
Year: 2013
Lodenafil improves hemodynamics and right ventricular remodeling in monocrotaline-induced model of pulmonary arterial hypertension in rats
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression
Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias
Year: 2018
The effect of curcumin on bleomycin-induced pulmonary fibrosis in rats
Source: Eur Respir J 2006; 28: Suppl. 50, 827s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept